2-(溴甲基)-3-硝基-苯甲酸 | 632340-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(溴甲基)-3-硝基-苯甲酸
• 英文名称: 2-bromomethyl-3-nitro-benzoic acid
• 英文别名: 2-(Bromomethyl)-3-nitrobenzoic acid
• CAS: 632340-56-8
• 化学式: C₈H₆BrNO₄
• 分子量: 260.044
• InChiKey: WNTCNOMUJRQWGP-UHFFFAOYSA-N

物化性质

• 熔点：
  209-211 °C
• 沸点：
  381.1±32.0 °C(Predicted)
• 密度：
  1.814±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(溴甲基)-3-硝基-苯甲酸 在 cesium fluoride 作用下， 以 乙腈 为溶剂， 反应 10.0h， 以60%的产率得到4-硝基苯酞
  参考文献：
  名称：

  An Alternative Method for the Synthesis of γ-Lactones by Using Cesium Fluoride-Celite/Acetonitrile Combination

  摘要：

  A variety of 2-(1-bromoalkyl) benzoic acids 4 undergo intramolecular nucleophilic substitution reaction when treated with a CsF-Celite as solid base in acetonitrile under reflux condition to give the corresponding cyclized phthalides in moderate to very good yield. These 2-(1-bromoalkyl) benzoic acids 4 are formed by the alpha-bromination of 2-alkylbenzoic acids 3 using N-bromosuccinimide and a catalytic amount of alpha,alpha'-azoisobutyronitrile in carbon tetrachloride under reflux.

  DOI：

  10.1081/scc-120024003
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸 在 N-溴代丁二酰亚胺(NBS) 、 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile 作用下， 以 四氯化碳 为溶剂， 反应 6.0h， 以53%的产率得到2-(溴甲基)-3-硝基-苯甲酸
  参考文献：
  名称：

  An Alternative Method for the Synthesis of γ-Lactones by Using Cesium Fluoride-Celite/Acetonitrile Combination

  摘要：

  A variety of 2-(1-bromoalkyl) benzoic acids 4 undergo intramolecular nucleophilic substitution reaction when treated with a CsF-Celite as solid base in acetonitrile under reflux condition to give the corresponding cyclized phthalides in moderate to very good yield. These 2-(1-bromoalkyl) benzoic acids 4 are formed by the alpha-bromination of 2-alkylbenzoic acids 3 using N-bromosuccinimide and a catalytic amount of alpha,alpha'-azoisobutyronitrile in carbon tetrachloride under reflux.

  DOI：

  10.1081/scc-120024003

文献信息

• [EN] METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS POUR LA SYNTHÈSE DE 3-[(DIHYDROISOINDOLINONE SUBSTITUÉE)-2-YL]-2,6-DIOXOPIPÉRIDINE ET INTERMÉDIAIRES CORRESPONDANTS
  申请人：NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD

  公开号：WO2010139266A1

  公开（公告）日：2010-12-09

  The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.

  本发明揭示了合成3-(取代二氢异吲哚酮-2-基)-2,6-二氧代哌啶及其中间体的方法，即合成式(I)化合物的方法，其中每个取代基固定在专利规范中定义。由于高生产率、对环境影响小和材料易得的优点，本发明的方法适用于工业生产。
• ISOINDOLYL COMPOUNDS
  申请人：Harris, III Ralph New

  公开号：US20120157494A1

  公开（公告）日：2012-06-21

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  式I的化合物：或其药用可接受盐，其中变量如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与P2X7嘌呤受体相关的疾病。
• [EN] ANHYDROUS LENALIDOMIDE FORM-I<br/>[FR] FORME I DE LÉNALIDOMIDE ANHYDRE
  申请人：NATCO PHARMA LTD

  公开号：WO2011111053A1

  公开（公告）日：2011-09-15

  Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1, 3-dihydro-isoindole-2-yl)-piperidine-2, 6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed.

  抗癌药物来那度胺的无水多晶形式-I，其化学名称为3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮，已被揭示。还披露了制备抗癌药物来那度胺的无水多晶形式-I的替代方法。
• Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels
  申请人：CELGENE CORPORATION

  公开号：EP2859895A1

  公开（公告）日：2015-04-15

  Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.

  2-(2,6-二氧代哌啶-3-基)邻苯二甲酰亚胺和1-氧代-2-(2,6-二氧代哌啶-3-基)异吲哚烷可以降低哺乳动物体内的TNFα水平。典型的实施例包括1-氧代-2-(2,6-二氧代-3-甲基哌啶-3-基)-4,5,6,7-四氟异吲哚烷和1,3-二氧代-2-(2,6-二氧代-3-甲基哌啶-3-基)-4-氨基异吲哚烷。
• ANHYDROUS LENALIDOMIDE FORM-I
  申请人：Konakanchi Durga Prasad

  公开号：US20130059889A1

  公开（公告）日：2013-03-07

  Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed.

  抗癌药物Lenalidomide的无水多晶形式-I被揭示，其化学名称为3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)-哌啶-2,6-二酮。还揭示了制备Lenalidomide无水多晶形式-I的替代方法。